INDIANAPOLIS , March 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio ® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, April 8 - 13, 2022 .
investor.lilly.com
investor.lilly.com
RSS Hunter
2022-03-08